Yeouido St. Mary's Hospital
6
2
2
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Remission of Type 2 Diabetes Via Calorie Restriction
Role: lead
Immunotherapy in Lymphoma
Role: collaborator
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Role: collaborator
Cohort of Inflammatory Bowel Disease Patient in Yeouido St. Mary's Hospital
Role: lead
CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)
Role: collaborator
Use of Ibandronate in Diabetic Patients
Role: lead
All 6 trials loaded